Welcome to our dedicated page for OmniAb SEC filings (Ticker: OABI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The OmniAb, Inc. (NASDAQ: OABI) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing investors with direct access to its official public record. OmniAb is a technology company that licenses discovery research platforms for antibody and peptide therapeutics, and its filings offer detail on how this business is structured and financed.
OmniAb’s current reports on Form 8-K include announcements of quarterly and year-to-date financial results, where the company breaks out revenue from license and milestone agreements, services, xPloration® instrument sales and related consumables, and royalties. These filings also discuss research and development and general and administrative expenses, other operating income, and net loss figures, giving context to the economics of its technology licensing and discovery services model.
Other 8-K filings describe material events such as securities purchase agreements for private placements of common stock. In these documents, OmniAb outlines the number of shares sold, purchase prices, intended use of proceeds for working capital and general corporate purposes, and related registration rights. Filings also confirm that OmniAb’s common stock is listed on The Nasdaq Global Market under the symbol OABI, with warrants listed on The Nasdaq Capital Market under OABIW, and that the company qualifies as an emerging growth company.
Shareholder-focused filings, including reports on annual meetings, provide voting results for director elections and ratification of the independent registered public accounting firm. Together, these SEC documents help investors analyze governance, capital structure, financing transactions, and the financial performance of OmniAb’s antibody discovery technology business. Stock Titan enhances this information with AI-powered summaries that explain key points from forms such as 10-K, 10-Q, 8-K, and ownership reports, helping readers quickly understand the implications of each filing.
FOEHR MATTHEW W reported multiple insider transaction types in a Form 4 filing for OABI. The filing lists transactions totaling 93,670 shares at a weighted average price of $1.70 per share. Following the reported transactions, holdings were 4,375,787 shares.
GUSTAFSON KURT A reported multiple insider transaction types in a Form 4 filing for OABI. The filing lists transactions totaling 33,912 shares at a weighted average price of $1.70 per share. Following the reported transactions, holdings were 259,402 shares.
Berkman Charles S reported multiple insider transaction types in a Form 4 filing for OABI. The filing lists transactions totaling 34,074 shares at a weighted average price of $1.70 per share. Following the reported transactions, holdings were 383,623 shares.
OABI filed a notice that an insider plans to sell common shares under Rule 144. The filing lists planned sales of 20,483 and 30,451 common shares through Morgan Stanley Smith Barney, with aggregate market values of
The shares come from restricted stock granted by the issuer as compensation, including 36,458 securities acquired on
Orchestra BioMed (OABI) insider Charles S. Berkman has filed a Rule 144 notice for planned stock sales. The filing covers intended sales of 6,891 and 9,541 shares of common stock through Morgan Stanley Smith Barney LLC on the NASDAQ around February 17 and 18, 2026, with stated aggregate market values of $11,714.70 and $16,219.70.
The shares to be sold were acquired as restricted stock compensation from the issuer, including 13,542 shares on February 16, 2026 and 18,750 shares on February 18, 2026. The notice also reports a prior sale on December 8, 2025 of 8,044 common shares for gross proceeds of $15,773.84. By signing, the seller represents that he is not aware of any undisclosed material adverse information about the company.
OABI insider Kurt A. Gustafson filed a notice of proposed sales under Rule 144 for common stock. The filing lists planned sales of 6,891 and 9,173 shares of common stock through Morgan Stanley Smith Barney on NASDAQ on 02/17/2026 and 02/18/2026, with aggregate market values of $11,714.70 and $15,594.10. The issuer had 143,955,400 shares of common stock outstanding. The shares to be sold were acquired as restricted stock compensation, including 13,542 shares on 02/16/2026 and 18,750 shares on 02/18/2026. The filing also notes a prior sale of 23,922 common shares on 12/08/2025 for gross proceeds of $46,909.73.
OmniAb, Inc. received an updated Schedule 13G/A showing that several related investment entities and individuals collectively hold meaningful passive stakes in its common stock. As of December 31, 2025, Robert Goldstein may have been deemed to beneficially own approximately 8.5% of OmniAb’s common shares, or 12,291,972 shares, through direct holdings and control positions in various entities. Ash X LP and its general partner RLG GP LLC each may have been deemed to beneficially own 7,557,202 shares, or about 5.3% of the company. RLG Capco II LLC may have been deemed to beneficially own 4,733,575 shares, or about 3.3%. Joel Greenblatt may have been deemed to beneficially own 1,429,766 shares, or about 1.0%. All percentages are based on 143,955,400 shares outstanding as of October 28, 2025. The reporting group certifies the holdings are in the ordinary course of business and not for the purpose of changing or influencing control of OmniAb.
OmniAb, Inc. director John L. Higgins reported the vesting of 13,172 restricted stock units (RSUs) and the corresponding acquisition of 13,172 shares of common stock on January 30, 2026.
The RSUs vest in three substantially equal annual installments beginning January 30, 2024, conditioned on his continued service. After this transaction, he beneficially owns 2,942,320 shares of common stock and 20,000 RSUs directly.
OmniAb, Inc. reports that its Board of Directors approved and adopted amended and restated bylaws effective January 30, 2026. The updated bylaws address the SEC’s universal proxy rules by clarifying that no one may solicit proxies for director nominees other than the Board’s nominees unless they comply with Rule 14a-19, including its notice and solicitation requirements.
The bylaws also modernize and enhance procedures for stockholder director nominations and other business at stockholder meetings, requiring additional background information and disclosures about proposing stockholders, proposed nominees, related persons, and their ownership of OmniAb securities. The filing notes further technical, modernizing and clarifying changes, with full text provided in attached exhibits.
OmniAb, Inc.'s Chief Legal Officer acquired 15,621 shares of common stock on December 7, 2025 through the vesting of restricted stock units. On December 8, 2025, 8,044 shares were sold at a weighted average price of $1.96 per share to cover tax withholding obligations in connection with that vesting under a required sell-to-cover arrangement that is not a discretionary trade.
After these transactions, the officer directly owns 377,071 shares of OmniAb common stock and holds 96,876 restricted stock units, each representing a contingent right to receive one share.